Prestige BioPharma Ltd. engages in the development and commercialization of biosimilars and antibody therapeutics. The firm develops antibody drugs for solid tumor, pancreatic cancer, and arthritis. Its product portfolio includes Herceptin, Avastin, and Humira biosimilars as well as anti-PAUF and anti-CTHRC1 antibodies. The company was founded in July 2005 and is headquartered in Singapore.